Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
446.9
USD
|
-2.20%
|
|
+0.23%
|
+9.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
56,303
|
61,457
|
55,834
|
74,127
|
104,849
|
117,917
|
-
|
-
|
Enterprise Value (EV)
1 |
52,495
|
54,798
|
48,309
|
63,349
|
93,630
|
103,944
|
99,326
|
94,200
|
P/E ratio
|
48.5
x
|
23
x
|
24.4
x
|
22.5
x
|
29.3
x
|
30
x
|
26.7
x
|
23.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.5
x
|
9.9
x
|
7.37
x
|
8.3
x
|
10.6
x
|
11
x
|
10.1
x
|
9.22
x
|
EV / Revenue
|
12.6
x
|
8.83
x
|
6.38
x
|
7.09
x
|
9.49
x
|
9.67
x
|
8.51
x
|
7.36
x
|
EV / EBITDA
|
27.7
x
|
15.2
x
|
10.8
x
|
12.8
x
|
20.6
x
|
19.3
x
|
17
x
|
14.3
x
|
EV / FCF
|
35.1
x
|
18.3
x
|
20.1
x
|
16.1
x
|
28.1
x
|
24.3
x
|
20.8
x
|
17.1
x
|
FCF Yield
|
2.85%
|
5.46%
|
4.99%
|
6.2%
|
3.56%
|
4.11%
|
4.8%
|
5.85%
|
Price to Book
|
9.38
x
|
7.07
x
|
5.53
x
|
5.33
x
|
5.96
x
|
5.48
x
|
4.71
x
|
4.1
x
|
Nbr of stocks (in thousands)
|
257,150
|
260,038
|
254,252
|
256,691
|
257,683
|
258,053
|
-
|
-
|
Reference price
2 |
219.0
|
236.3
|
219.6
|
288.8
|
406.9
|
457.0
|
457.0
|
457.0
|
Announcement Date
|
1/30/20
|
2/1/21
|
1/26/22
|
2/7/23
|
2/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,163
|
6,206
|
7,574
|
8,931
|
9,869
|
10,754
|
11,672
|
12,793
|
EBITDA
1 |
1,893
|
3,601
|
4,470
|
4,941
|
4,556
|
5,374
|
5,840
|
6,576
|
EBIT
1 |
1,786
|
3,491
|
4,344
|
4,793
|
4,375
|
5,052
|
5,453
|
6,200
|
Operating Margin
|
42.9%
|
56.25%
|
57.35%
|
53.67%
|
44.33%
|
46.98%
|
46.72%
|
48.46%
|
Earnings before Tax (EBT)
1 |
1,395
|
3,117
|
2,730
|
4,232
|
4,380
|
4,883
|
5,552
|
6,409
|
Net income
1 |
1,177
|
2,712
|
2,342
|
3,322
|
3,620
|
3,994
|
4,462
|
5,098
|
Net margin
|
28.27%
|
43.7%
|
30.92%
|
37.2%
|
36.68%
|
37.14%
|
38.23%
|
39.85%
|
EPS
2 |
4.510
|
10.29
|
9.010
|
12.82
|
13.89
|
15.22
|
17.09
|
19.35
|
Free Cash Flow
1 |
1,494
|
2,994
|
2,408
|
3,925
|
3,337
|
4,270
|
4,769
|
5,510
|
FCF margin
|
35.89%
|
48.24%
|
31.8%
|
43.95%
|
33.81%
|
39.71%
|
40.86%
|
43.07%
|
FCF Conversion (EBITDA)
|
78.92%
|
83.15%
|
53.89%
|
79.44%
|
73.24%
|
79.45%
|
81.65%
|
83.79%
|
FCF Conversion (Net income)
|
126.94%
|
110.4%
|
102.84%
|
118.16%
|
92.19%
|
106.91%
|
106.86%
|
108.08%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/30/20
|
2/1/21
|
1/26/22
|
2/7/23
|
2/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,073
|
2,098
|
2,196
|
2,334
|
2,303
|
2,375
|
2,493
|
2,484
|
2,518
|
2,691
|
2,663
|
2,687
|
2,734
|
2,718
|
2,780
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,215
|
1,210
|
1,390
|
1,310
|
1,269
|
1,243
|
-
|
-
|
EBIT
1 |
1,124
|
1,166
|
1,187
|
1,289
|
1,150
|
902.3
|
1,148
|
1,173
|
1,151
|
1,336
|
1,252
|
1,232
|
1,229
|
1,332
|
1,387
|
Operating Margin
|
54.23%
|
55.61%
|
54.05%
|
55.24%
|
49.95%
|
37.99%
|
46.04%
|
47.24%
|
45.73%
|
49.67%
|
47.01%
|
45.83%
|
44.96%
|
49%
|
49.9%
|
Earnings before Tax (EBT)
1 |
870.9
|
954.8
|
1,024
|
1,176
|
1,077
|
891.5
|
1,162
|
1,179
|
1,148
|
1,279
|
1,221
|
1,192
|
1,212
|
1,349
|
1,413
|
Net income
1 |
770.1
|
762.1
|
810.5
|
930.5
|
818.9
|
699.8
|
915.7
|
1,035
|
968.8
|
1,100
|
986.4
|
951.4
|
941.9
|
1,081
|
1,132
|
Net margin
|
37.16%
|
36.33%
|
36.9%
|
39.86%
|
35.56%
|
29.47%
|
36.73%
|
41.69%
|
38.48%
|
40.87%
|
37.04%
|
35.4%
|
34.45%
|
39.77%
|
40.74%
|
EPS
2 |
3.000
|
2.960
|
3.130
|
3.590
|
3.150
|
2.690
|
3.520
|
3.970
|
3.710
|
4.210
|
3.769
|
3.641
|
3.614
|
4.130
|
4.320
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/26/22
|
5/5/22
|
8/4/22
|
10/27/22
|
2/7/23
|
5/1/23
|
8/1/23
|
11/6/23
|
2/5/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3,808
|
6,659
|
7,525
|
10,779
|
11,218
|
13,974
|
18,592
|
23,717
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,494
|
2,994
|
2,409
|
3,925
|
3,337
|
4,270
|
4,769
|
5,510
|
ROE (net income / shareholders' equity)
|
22.4%
|
36.7%
|
36%
|
32.1%
|
23%
|
22.4%
|
19.5%
|
19.4%
|
ROA (Net income/ Total Assets)
|
16.2%
|
27%
|
18.8%
|
21%
|
17.7%
|
15.3%
|
13.7%
|
13%
|
Assets
1 |
7,282
|
10,035
|
12,433
|
15,792
|
20,441
|
26,041
|
32,595
|
39,275
|
Book Value Per Share
2 |
23.30
|
33.40
|
39.70
|
54.10
|
68.20
|
83.40
|
96.90
|
112.0
|
Cash Flow per Share
2 |
6.020
|
12.40
|
10.20
|
15.90
|
13.60
|
18.80
|
19.10
|
20.30
|
Capex
1 |
75.5
|
260
|
235
|
205
|
200
|
214
|
222
|
227
|
Capex / Sales
|
1.81%
|
4.19%
|
3.1%
|
2.29%
|
2.03%
|
1.99%
|
1.91%
|
1.77%
|
Announcement Date
|
1/30/20
|
2/1/21
|
1/26/22
|
2/7/23
|
2/5/24
|
-
|
-
|
-
|
Average target price
462.8
USD Spread / Average Target +1.28% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.83% | 118B | | +10.80% | 106B | | -10.84% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.11% | 15.97B | | +6.62% | 14.03B | | +17.53% | 11.67B | | -30.73% | 7.55B |
Bio Therapeutic Drugs
|